Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Galapagos (GLPG) today and set a price target of $226.00. The company's shares closed
Akorn (NASDAQ:AKRX) and GALAPAGOS NV/S (NASDAQ:GLPG) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuati
Alliancebernstein L.P. reduced its position in shares of GALAPAGOS NV/S (NASDAQ:GLPG) by 46.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Com

Is Galapagos Stock a Buy?

12:09pm, Sunday, 12'th Apr 2020
Investors may want to own this biotech before its lead drug gets approved.
Gilead Sciences has signed an agreement with South San Francisco biotech Second Genome to use its microbiome drug development expertise to advance the
In February, GILD divulged it was providing remdesivir to coronavirus patients on an emergency basis. GILD is up by double digits since then. The upside could d
Following up on its initial announcements in January and February, Incyte (NASDAQ:INCY) reports detailed results from two successful Phase 3 clinical trials, TRuE-AD1 and TRuE-AD2, evaluating a topica
Cubist Systematic Strategies LLC lifted its position in shares of GALAPAGOS NV/S (NASDAQ:GLPG) by 172.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Co
BioSig Technologies (NASDAQ:BSGM) initiated with Buy rating and $9 (75% upside) price target at Roth Capital.Amgen (NASDAQ:AMGN) upgraded to Outperform with a $255 (29% upside) price target at Raymond
If a safe and effective treatment for COVID-19 is close at hand, it will likely come from one of these two biotechs.

Goldman likes McKesson in premarket analyst action

11:53am, Wednesday, 18'th Mar 2020
Osmotica Pharmaceuticals (NASDAQ:OSMT) initiated with Buy rating and $8 (74% upside) price target at SunTrust.Epizyme (NASDAQ:EPZM) added to Best Ideas List at Wedbush with a $30 (68% upside) price ta
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE